New hope for ALS patients: expanded access to experimental drug SPG302
Disease control
AVAILABLE
This program offers SPG302, an experimental drug, to adults with ALS who cannot join other clinical trials. The goal is to check if the drug is safe and can help slow the disease. Participants must have a confirmed ALS diagnosis and be between 18 and 80 years old.
Sponsor: Spinogenix • Aim: Disease control
Last updated May 15, 2026 11:54 UTC